The 13th Annual Koch Institute Summer Symposium, “RNA Biology, Cancer and Therapeutic Implications,” took place on Friday, June 13, 2014 at Kresge Auditorium on the MIT campus in Cambridge, Massachusetts. The symposium focused on the molecular and cellular mechanisms underlying RNA-based gene regulation in cancer. More than 1,000 cancer researchers, RNA biologists, and clinical oncologists convened to hear updates on the latest breakthroughs in the creation of RNA-based gene-editing tools and the development and intracellular delivery of RNA-cancer medicines.
Speakers and Presentations
Tyler Jacks, PhD Director, Koch Institute for Integrative Cancer Research David H. Koch Professor of Biology, Massachusetts Institute of Technology Investigator, Howard Hughes Medical Institute
Sangeeta Bhatia, MD, PhD John J. and Dorothy Wilson Professor of Health Sciences and Technology & Electrical Engineering and Computer Science, Massachusetts Institute of Technology Director, Laboratory for Multiscale Regenerative Technologies, Koch Institute for Integrative Cancer Research Investigator, Howard Hughes Medical Institute
Daniel Anderson, PhD Samuel A. Goldblith Professor of Applied Biology and Associate Professor, Chemical Engineering and Institute for Medical Engineering and Science, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
Progress in Advancement of RNAi Therapeutics
John Maraganore, PhD CEO and Director, Alnylam Pharmaceuticals
Scott Lowe, PhD Associate Director for Basic Cancer Research, Cancer Biology and Genetics Program; Chair, Geoffrey Beene Cancer Research Center, Memorial Sloan-Kettering Cancer Center Investigator, Howard Hughes Medical Institute